ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
6.16
-0.07 (-1.12%)
At close: Jan 17, 2025, 4:00 PM
6.42
+0.26 (4.22%)
Pre-market: Jan 21, 2025, 4:01 AM EST
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 6.79M EUR in the half year ending June 30, 2024, with 204.58% growth. This brings the company's revenue in the last twelve months to 9.03M, up 100.87% year-over-year. In the year 2023, ABIVAX Société Anonyme had annual revenue of 4.49M with 0.38% growth.
Revenue (ttm)
9.03M EUR
Revenue Growth
+100.87%
P/S Ratio
n/a
Revenue / Employee
148,049 EUR
Employees
61
Market Cap
411.78M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.49M | 17.00K | 0.38% |
Dec 31, 2022 | 4.48M | 273.00K | 6.50% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | -7.00K | -822.00K | -100.86% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ABVX News
- 11 days ago - Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment - GlobeNewsWire
- 4 weeks ago - Abivax Announces a Change to the Composition of its Board of Directors - GlobeNewsWire
- 2 months ago - Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - GlobeNewsWire
- 2 months ago - Abivax presents third quarter 2024 key financial information - GlobeNewsWire
- 2 months ago - Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - GlobeNewsWire
- 3 months ago - Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - GlobeNewsWire
- 3 months ago - Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease - GlobeNewsWire
- 3 months ago - Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - GlobeNewsWire